CN215019792U - Medicine elution bracket externally covered with absorbable net - Google Patents

Abstract

The utility model relates to the technical field of medical treatment, in particular to a drug eluting stent externally coated with an absorbable mesh, which comprises a stent, a drug coating and an externally coated mesh; the drug coating is coated on the outer surface of the stent; the outer covering net covers the outside of the bracket and can be absorbed and degraded by the human body. After the stent is implanted into a human body, the medicine coating is used for treating the pathological change position of the human body, and the outer covering net can be absorbed by the human body, so that the endothelialization process of the stent is accelerated, the risk of thrombus in the stent is reduced, the risk of local inflammatory reaction caused by long-term existence of the material of the outer covering net is avoided, the occurrence of no reflow and slow blood flow in interventional therapy of pathological changes with high risk of distal embolism such as coronary thrombosis, blood vessels and the like can be reduced, meanwhile, the absorption of the outer covering net is combined with a medicine elution stent to compare with the existing product, and the risk of late thrombosis and restenosis in the stent is greatly reduced.

Description

Medicine elution bracket externally covered with absorbable net

Technical Field

The utility model belongs to the technical field of the medical treatment technique and specifically relates to a drug eluting support that covers absorbable mesh outward.

Background

Cardiovascular diseases become the first killer of national health of China in recent years, and seriously threaten the health of people. The minimally invasive interventional diagnosis and treatment technology is an important contribution of medicine to human civilization at the end of the 20 th century, and is particularly remarkable in the aspect of treating coronary heart disease. The minimally invasive intervention treatment is mainly coronary artery stent implantation. The treatment does not need thoracotomy, general anesthesia and cardiopulmonary bypass, the operation is carried out under an X-ray screen, the patient keeps clear-headed, and an operator inserts a special balloon catheter and a stent into the peripheral artery of the patient through percutaneous puncture to achieve the effects of coronary artery of the patient, dilating the narrow pathological change part, releasing a stent system, repairing blood vessels and recovering the function of the coronary artery.

No-reflow and slow blood flow in percutaneous coronary intervention (PC I) procedures are serious complications of surgery, possibly leading to perioperative acute myocardial infarction, with serious adverse consequences and even death. The slow blood flow and no-reflow phenomena in coronary stenting are common in patients with severe thrombus load in acute myocardial infarction, patients with severe atherosclerotic plaque load in coronary arteries, and patients with bridged vessel disease. The main reason for the occurrence of the complications is that the coronary lesion area is extruded in the expansion process of the stent, so that components such as atherosclerotic plaques, lipid components, thrombus and the like in the area are broken and fall off to form larger microparticles, capillary vessels at the far end of the blood vessels are blocked, microcirculation is disturbed, and slow blood flow and no backflow phenomenon are caused.

In response to this clinical dilemma, medical workers attempt to reduce the occurrence of slow blood flow and no-reflow phenomena and improve the outcome of treatment for patients by using various means such as distal protection devices, thrombus aspiration, stent grafts, and the like. However, the covered stent may cause the occlusion of a branch blood vessel, the endothelialization of the covered stent is difficult, and the risk of long-term thrombosis is high; thrombus aspiration can cause thrombus displacement and cause other important organ embolism risks (such as cerebral infarction and the like); the operation of the remote protection device is complex, and clear evidence for improving the slow blood flow phenomenon is lacked. Thus, there has been a lack of effective means of reducing the risk of recurrent thrombosis, bridge vessel lesions, and high plaque load lesions in clinical work.

Current clinical studies show that: the MGuard metal-covered bare stent remarkably reduces the risks of slow blood flow and no backflow in acute myocardial infarction and vein bridge vascular interventional therapy, but long-term follow-up shows that the MGuard metal-covered bare stent increases the risk of thrombus and restenosis in subacute stents, and the mechanism comprises that the small-aperture mesh covered outside delays the endothelialization of the stent and increases the risk of thrombus; the prolonged persistence of the microfiber outer membrane exacerbates the local inflammatory stimulus.

SUMMERY OF THE UTILITY MODEL

An object of the utility model is to provide a drug eluting stent covered with absorbable mesh outside to solve the above technical problem existing in the prior art.

In order to solve the technical problem, the drug eluting stent covered with the absorbable mesh comprises a stent, a drug coating and the covered mesh; the drug coating is coated on the outer surface of the stent; the outer covering net covers the stent, and the outer covering net can be absorbed and degraded by the human body.

Further, the stent is made of a cobalt-chromium alloy material, and the drug coating is a rapamycin derivative.

Further, the material of the outer covering net is magnesium, poly lactose or iron.

Further, the outer cover comprises a plurality of connecting lines arranged in sequence; the connecting line is bent in a wave shape, so that the connecting line forms a plurality of convex parts and concave parts at intervals; and one convex part of the last connecting wire is sleeved on the two concave parts of the next connecting wire.

Further, the convex part and the concave part are both triangular.

Further, the bracket is formed by a plurality of fixing frames which are arranged at intervals; the fixing frame is wavy and is in a closed ring shape; two adjacent fixing frames are fixed through a connecting frame.

Furthermore, the fixing frame is provided with a reinforcing strip, and the reinforcing strip is arranged at the bending part of the fixing frame.

Adopt above-mentioned technical scheme, the utility model discloses following beneficial effect has:

the utility model provides a medicine elution support, after the support implantation is human, the medicine coating is handled human pathological change position, covers the net and can be absorbed by the human body outside to the endothelialization process in the support with higher speed has reduced the interior thrombus risk of support, has avoided covering net material to exist for a long time and has leaded to local inflammatory reaction risk, has reduced the risk of restenosis. The outer covering net can effectively press thrombus in coronary artery at the early stage of implantation, so that slow blood flow of coronary artery caused by falling of thrombus and no risk of re-flowing are avoided, and the outer covering net is gradually degraded after thrombus is stabilized and organized without influencing endothelialization process. Therefore, the design of the absorbable outer covering net enables the novel stent to reduce the occurrence of no re-flowing and slow blood flow in interventional therapy of coronary thrombosis lesion, bypass vessel and other lesion with high risk of distal embolism, and meanwhile, the absorption of the outer covering net is combined with a drug elution stent to compare with the existing product, thereby greatly reducing the risk of late thrombosis and restenosis in the stent.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the embodiments or the description in the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.

Fig. 1 is a schematic structural diagram of a drug eluting stent provided in an embodiment of the present invention;

fig. 2 is a schematic structural view of an outer covering net according to an embodiment of the present invention;

fig. 3 is a schematic structural diagram of a bracket according to an embodiment of the present invention.

Reference numerals:

1-a scaffold; 2-drug coating; 3-outer covering net;

4-connecting wires; 5-a boss; 6-a recess;

7-a fixing frame; 8-connecting frame.

Detailed Description

The technical solution of the present invention will be described clearly and completely with reference to the accompanying drawings, and obviously, the described embodiments are some, but not all embodiments of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by a person skilled in the art without creative work belong to the protection scope of the present invention.

In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", and the like indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, and are only for convenience of description and simplification of description, but do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus, should not be construed as limiting the present invention. Furthermore, the terms "first," "second," and "third" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.

In the description of the present invention, it is to be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, and may be, for example, fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meaning of the above terms in the present invention can be understood in specific cases to those skilled in the art.

The present invention will be further explained with reference to specific embodiments.

As shown in fig. 1-3, the present example provides a drug eluting stent coated with an absorbable mesh, comprising a stent 1, a drug coating layer 2, and an outer coated mesh 3; the drug coating 2 is coated on the outer surface of the stent 1; the outer covering net 3 covers the stent 1, and the outer covering net 3 can be absorbed and degraded by the human body.

According to the drug eluting stent 1 provided by the embodiment, after the stent 1 is implanted into a human body, the drug coating 2 treats the position of the human body, and the outer covering net 3 can be absorbed by the human body, so that the endothelialization process of the stent 1 is accelerated, the risk of thrombus in the stent 1 is reduced, the risk of local inflammatory reaction caused by the long-term existence of the material of the outer covering net 3 is avoided, and the risk of restenosis is reduced. The outer covering net 3 can effectively press thrombus in coronary artery at the early stage of implantation, so that slow blood flow of the coronary artery caused by falling of the thrombus and no risk of re-flowing are avoided, and the outer covering net 3 is gradually degraded after the thrombus is stabilized and organized without influencing the endothelialization process. Therefore, the novel stent can reduce the occurrence of no reflow and slow blood flow in interventional therapy of lesions with high risk of distal embolism such as coronary thrombosis lesion, blood bridge and the like through the design of the absorbable outer covering net 3, and simultaneously, compared with the prior product, the absorption combined drug elution stent of the outer covering net 3 greatly reduces the risk of late thrombosis and restenosis in the stent 1.

The utility model provides a medicine elution support can be used for among the interventional therapy of other pathological changes such as coronary aneurysm, coronary perforation, carotid artery support 1 implantation.

Wherein, the stent 1 is made of cobalt-chromium alloy material, and the drug coating 2 is rapamycin derivative. In this embodiment, the support 1 made of cobalt-chromium alloy provides sufficient radial supporting force and simultaneously makes the steel beam of the support 1 thinner, so that the trafficability of the support 1 is better. The rapamycin derivative serving as the drug coating 2 can play a role in inhibiting smooth muscle proliferation and inhibiting restenosis, thereby improving the treatment effect.

The material of the outer covering net 3 is magnesium, poly lactose or iron. In this embodiment, the outer covering net 3 may be made of an alloy material or a bioabsorbable material, and may be made of magnesium, poly-lactose, or iron, preferably, the outer covering net 3 is made of a magnesium net, and has a high content of magnesium ions in human tissues, high tissue compatibility, fast biodegradation, low inflammatory reaction caused, and a better effect.

As shown in fig. 2, further, the outer cover 3 includes a plurality of connecting lines 4 arranged in sequence; the connecting wire 4 is bent in a wave shape, so that the connecting wire 4 forms a plurality of spaced convex parts 5 and concave parts 6; one convex part 5 of the previous connecting line 4 is sleeved on two concave parts 6 of the next connecting line 4. In this embodiment, the outer covering net 3 is formed by connecting a plurality of connecting lines 4 in sequence, wherein the connecting mode of the connecting lines 4 is that one convex part 5 of the last connecting line 4 is sleeved on two concave parts 6 of the next connecting line 4, so that two adjacent connecting lines 4 are connected and buckled together, and the outer covering net 3 formed in this way has good performance and is not easy to break.

Furthermore, the convex part 5 and the concave part 6 are both triangular, so that the aperture on the outer covering net 3 is larger, the medicine in the medicine coating 2 part can flow out from the aperture conveniently, and the treatment effect is improved.

As shown in fig. 3, further, the bracket 1 is formed by a plurality of fixing frames 7 arranged at intervals; the fixing frame 7 is wave-shaped, and the fixing frame 7 is closed ring-shaped; two adjacent fixing frames 7 are fixed through a connecting frame 8. In this embodiment, support 1 is connected gradually by a plurality of annular mounts 7 and link 8 and forms, and the manufacturing of being convenient for, mount 7 are the wave, and its support body steadiness is high, and support effect is good.

Furthermore, a reinforcing strip is arranged on the fixing frame 7, and the reinforcing strip is arranged at the bending part of the fixing frame 7. In this embodiment, the reinforcing strip plays a role in reinforcing the fixing frame 7, so that the supporting effect of the fixing frame 7 is better.

Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; although the present invention has been described in detail with reference to the foregoing embodiments, it should be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention.

Claims (7)

1. A drug eluting stent coated with an absorbable mesh, which is characterized by comprising a stent, a drug coating and the outer coated mesh;

the drug coating is coated on the outer surface of the stent; the outer covering net covers the stent, and the outer covering net can be absorbed and degraded by the human body.

2. The drug eluting stent covered with an absorbable mesh according to claim 1, wherein the stent is a cobalt chromium alloy material and the drug coating is a rapamycin derivative.

3. The drug eluting stent with an outer covering absorbable mesh of claim 2, wherein the material of the outer covering mesh is magnesium, poly lactose or iron.

4. The drug eluting stent with an outer absorbable mesh according to claim 1, wherein the outer covering comprises a plurality of connecting lines arranged in sequence; the connecting line is bent in a wave shape, so that the connecting line forms a plurality of convex parts and concave parts at intervals; and one convex part of the last connecting wire is sleeved on the two concave parts of the next connecting wire.

5. The drug eluting stent covered with an absorbable mesh according to claim 4, wherein the protrusions and the depressions are triangular.

6. The drug eluting stent covered with an absorbable mesh according to claim 1, wherein the stent is formed by a plurality of spaced apart fixation frames; the fixing frame is wavy and is in a closed ring shape; two adjacent fixing frames are fixed through a connecting frame.

7. The drug eluting stent covered with an absorbable mesh as claimed in claim 6, wherein the fixing frame is provided with a reinforcing strip, and the reinforcing strip is arranged at the bending part of the fixing frame.

Images